Department of Oncological Surgery, Veneto Oncological Institute (IOV-IRCCS), Via Gattamelata 64, 35128, Padova, Italy.
World J Surg. 2010 Jul;34(7):1629-36. doi: 10.1007/s00268-010-0490-8.
Inflammatory bowel disease (IBD) and colorectal surgery are risk factors for deep venous thrombosis (DVT). The aim of this prospective study was to evaluate the effectiveness of standardized prophylactic low molecular weight heparin (LMWH) therapy in patients who underwent surgery for ulcerative colitis (UC) and Crohn's disease (CD).
Since 1999 all patients operated on for colorectal diseases in our institute have received 4,000 IU/day LMWH from the day of operation to discharge. The complete series of patients who had major colorectal surgery from 1999 until 2006 were reviewed for overt DVT episodes. Furthermore, 60 consecutive patients who were admitted for surgery for IBD were prospectively enrolled in the 2004-2006 period. Each patient underwent venous color Doppler ultrasound scan at admission and at discharge. Demographic data, disease activity, and clotting parameters were collected. Data were analyzed with Spearman's correlation test, multiple regression, and receiver operating characteristics (ROC) curves analysis.
The rate of DVT in UC patients was significantly higher than in colorectal cancer patients (p = 0.009), and the odds ratio (OR) for postoperative DVT in UC patients was 7.4 (95% CI 1.4-44.4; p = 0.017). Female gender, UC diagnosis, active rectal bleeding, aPTT value, aCL IgM, abeta2 IgM, and pANCA levels significantly correlated with postoperative DVT. At multivariate analysis only aCL IgM levels were found to be independently associated with postoperative DVT (p = 0.05).
In conclusion, our study showed that prophylactic therapy with 4,000 IU/day LMWH was not completely effective for the prevention of postoperative DVT in patients with CD, and even less so in those with UC. In these patients, a more tailored prophylactic therapy should be considered, and further randomized controlled trials testing the effectiveness of different prophylactic protocols would be advisable. Furthermore, aCL IgM serum levels might be helpful in identifying IBD patients who are at higher risk of postoperative DVT.
炎症性肠病(IBD)和结直肠手术是深静脉血栓形成(DVT)的危险因素。本前瞻性研究的目的是评估标准化预防用低分子肝素(LMWH)治疗在溃疡性结肠炎(UC)和克罗恩病(CD)接受手术的患者中的有效性。
自 1999 年以来,我们研究所接受结直肠疾病手术的所有患者在手术当天至出院时每天接受 4000IU/LMWH。回顾了 1999 年至 2006 年期间所有接受大肠大手术的患者中显性 DVT 发作的完整系列。此外,2004-2006 年期间前瞻性纳入了 60 例因 IBD 接受手术的连续患者。每位患者在入院时和出院时均进行静脉彩色多普勒超声扫描。收集人口统计学数据、疾病活动度和凝血参数。采用 Spearman 相关检验、多元回归和接收者操作特征(ROC)曲线分析对数据进行分析。
UC 患者的 DVT 发生率明显高于结直肠癌患者(p = 0.009),UC 患者术后 DVT 的优势比(OR)为 7.4(95%CI 1.4-44.4;p = 0.017)。女性、UC 诊断、活动性直肠出血、APTT 值、抗心磷脂 IgM、抗β2 糖蛋白 IgM 和 pANCA 水平与术后 DVT 显著相关。多变量分析仅发现抗心磷脂 IgM 水平与术后 DVT 独立相关(p = 0.05)。
总之,我们的研究表明,每天 4000IU/LMWH 的预防性治疗对预防 CD 患者术后 DVT 不完全有效,对 UC 患者更是如此。在这些患者中,应考虑更有针对性的预防治疗,并且进一步测试不同预防方案有效性的随机对照试验是明智的。此外,抗心磷脂 IgM 血清水平可能有助于识别术后 DVT 风险较高的 IBD 患者。